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ABSTRACT
Establishing the role of DC-SIGN and glycoprotein H for KSHV entry in B lymphocytes

by Nancy Palmerin
Kaposi sarcoma-associated herpesvirus, also known as KSHV or HHV-8, is an emerging pathogen
and the causative agent of multiple cancers in immunocompromised patients. KSHV is known
to cause four types of malignancies: endothelial-based Kaposi Sarcoma (KS), two rare B cellbased lymphomas; Primary effusion lymphoma, Multicentric Castleman’s disease and a recently
characterized inflammatory disorder called KSHV-associated inflammatory cytokine syndrome
(KICS). Unfortunately, all of the diseases associated with KSHV infection are fatal, and to this
day there is no known cure. The purpose of this study is to understand the viral entry process of
KSHV in tonsil-derived B lymphocytes. This study will particularly explore the role of KSHV
glycoprotein gH and cell surface receptor DC-SIGN.
The first aim of this project will investigate whether the cell surface receptor, DC-SIGN, is required
for viral entry of KSHV on tonsillar B lymphocytes. Various approaches will be performed. First,
characterization of tonsillar B lymphocytes subsets that express DC-SIGN will take place via
flow cytometry followed by analysis on whether KSHV can infect DC-SIGN+ or DC-SIGN- B
cells. Second, manipulation of DC-SIGN will be performed utilizing a Neutralizing antibody (antiDC-SIGN), to observe the change in KSHV infection on tonsillar B lymphocytes. Lastly, a DCSIGN depletion strategy will be performed to vigorously answer the question of whether DCSIGN is required for KSHV entry. The second aim that will be addressed is whether the KSHV
glycoprotein H (gH) is required for entry into tonsil derived B lymphocytes. In vitro infection of
tonsil derived B lymphocytes with a mutant KSHV virus that lacks gH, but retains all the other
essential KSHV glycoproteins (KSHV-∆gH) will be performed and analyzed via flow cytometry.
We will also combine these approaches with the KSHV-∆gH mutant virus in order to determine
V

whether manipulation of DC-SIGN affects entry of this mutant into B lymphocytes. This study
will help understand the initial modes of KSHV transmission in tonsillar B lymphocytes which is
relatively understudied in the field and pave the way for the development of future therapeutics to
prevent KSHV transmission.
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CHAPTER I - INTRODUCTION

1.1 Herpesviruses
Herpesviruses are a family of DNA viruses known to infect both animals and humans [4].There
are a total of eight herpes viruses known to infect humans: Herpes Simplex Virus 1 (HSV-1),
Herpes Simplex Virus 2( HSV-2), Varicella-Zoster Virus (VZV), Epstein-Barr virus (EBV),
cytomegalovirus (CMV), human herpesvirus 6 (HHV-6), human herpesvirus 7 (HHV-7), and
Kaposi Sarcoma Herpes Virus (KSHV)[4]. These eight human herpesviruses belong to the
Herpesviridae family of DNA viruses [4], and are divided into 3 subfamilies: Alphaherpesvirinae,
Betaherpesvirinae, and Gammaherpesvirnae based on their biological properties (Figure 1) [5].
Members of Alphaherpesvirinae are Herpes Simplex Virus 1 (HSV-1), Herpes Simplex Virus 2
(HSV-2), and Varicella-zoster virus (VZV) [6]. These particular viruses are known to infect a broad
host of cell types and are known to be neuroinvasive. Alphaherpesvirinae infection and replication
predominantly occurs in epithelial cells. Subsequently transmission of viral infection occurs in
the neurons, where the virus is known to establish persistent infection in the nerves [7]. Herpes
simplex virus 1 and Herpes simplex virus 2 can be classified as sexually transmitted diseases and
are the major causes of cold sores and genital herpes [6]. Varicella-zoster virus is responsible for
shingles (herpes zoster) and chickenpox (varicella) [8].
Members of Betaherpesvirinae are: Cytomegalovirus, Human Herpesvirus 6, and Human
Herpesvirus 7 [9]. These viruses have a stringent cellular tropism towards: epithelial cells,
fibroblasts, monocytes, lymphocytes, and T cells but are also lymphotropic where they have
extensive reproductive cycles [10].Cytomegalovirus is linked to infections in the nervous system
and is known to cause congenital infections and mononucleosis [11]. Human Herpesvirus 6 is the
causative agent of Roseola infantum, a nonmalignant rash found predominantly in infants [12].
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Figure 1. Phylogenetic tree for the family Herpesviridae, divided into the alphaherpesviruses (α) beta
herpesviruses(β) and gammaherpesviruses (γ) sub-families. Adapted from: [1]

Human Herpesvirus 7 is associated with various muscular rashes in children [13]. Both Human
Herpesvirus 6 & Human Herpesvirus 7 bring clinical manifestations such as seizures, fevers, and
rashes [14].Members of Gammaherpesvirinae are Epstein-Barr virus (EBV), and Kaposi Sarcoma
Herpes Virus (KSHV). EBV and KSHV are known to have the most limited host range [15]. This
particular class of herpesviruses are the only members known to infect lymphocytes, but also infect
a variety of non-lymphocyte cell types, and are associated with human cancers [15]. Overall, all
herpes viruses share similar characteristics but the most common are: structure of the virion, latent
and lytic life cycles, cascade system of gene expression, assembly, and imperceptible infection [1].
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1.2 Kaposi Sarcoma Human Herpesvirus
Kaposi Sarcoma-associated herpesvirus (KSHV, or HHV-8) is an oncogenic virus which is
widely known for its association with the Acquired Immunodeficiency Syndrome/ Human
Immunodeficiency Virus ( AIDS/HIV) epidemic [16]. Kaposi Sarcoma (KS) was first discovered
in 1872 by physician, Dr. Moritz Kaposi, where he characterized a Kaposi Sarcoma tumor as
an aggressive tumor with multi pigmented skin lesions [17]. Before the AIDS epidemic, Kaposi
Sarcoma was a rare neoplasm that primarily infected elderly men in Eastern Europe and the
Mediterranean [5]. In 1994, Chang et al. revealed that Kaposi Sarcoma Herpes Virus was the
etiological agent of Kaposi Sarcoma. KSHV was identified through polymerase chain reactionbased subtractive analysis where a KS lesion of an AIDS patient was removed via biopsy and
compared to the patient’s unaffected skin [18] .
KSHV is now known to cause several types of human malignancies that are primarily present in
people that are immunosuppressed or have acquired immunodeficiency syndrome (AIDS). The
human malignancies are: Kaposi Sarcoma (KS) ,Primary effusion lymphoma (PEL), Multicentric
Castleman’s disease (MCD) and a recently characterized inflammatory disorder called KSHVassociated inflammatory cytokine syndrome (KICS) [19]. Kaposi Sarcoma is the most common
KSHV-associated tumor. Kaposi Sarcoma can be described as an endothelial based cancer with
distinctive multicentric angioproliferative spindle cell lesions [20]. There are four distinct variants of
Kaposi Sarcoma: Classical Kaposi Sarcoma, Endemic Kaposi Sarcoma, Iatrogenic Kaposi Sarcoma
and AIDS associated Kaposi Sarcoma . These four variants differ in the severity of infection and the
extent on which the patient has immunosuppression [20] . Classical KS is described as a rare form
of Kaposi Sarcoma that is prevalent in HIV negative elderly patients in Eastern European regions,
the Mediterranean, and Middle Eastern origin [5]. Endemic Kaposi Sarcoma is predominantly in
Africa, infecting HIV negative children, men, and women [21]. Iatrogenic Kaposi Sarcoma, also
known as transplant KS, develops in patients that undergo immunosuppressive therapy after organ
transplantation. AIDS associated Kaposi Sarcoma commonly develops in HIV infected individuals
and is a major cause of death in these patients [22].
3

PEL and MCD can be described as two B-cell based lymphoproliferative disorders associated with
KSHV [16]. PEL is a true clonal lymphoma and develops in the body as peritoneal, pleural, and
pericardial effusions [23]. While MCD is a polyclonal reactive lymphoproliferative disease that
manifests as follicular and vascular alterations in the lymph nodes. Besides these two disorders
caused by KSHV there is a newly characterized condition known as KICS. KICS and MCD have
similar presentations with overproduction of certain inflammatory cytokines i.e Interleukin 6 and
Interleukin 10 ( IL-6 and IL-10) but KICS lacks pathologic evidence associated with MCD [20].
Distribution of KSHV infection varies geographically [24]. Prevalence of KSHV parallels the
prevalence of Kaposi Sarcoma [24]. In the adult population, KSHV infection is found to be present
in sub-Saharan Africa at >80% seroprevalence, 30% in the Mediterranean, at 10% in Western
and 8% Northern Europe [25, 26]. It should be noted that the seroprevalence of KS increases
drastically in KS patients that are infected with HIV [27]. Studies have shown KS patients that are
HIV positive may display seropositive results for infection during initial examination but upon
retesting, KS individuals display seronegative results.These results reveal that negative serology is
not always indicative of lack of infection [28].
1.3 Kaposi Sarcoma Herpesvirus Transmission
Despite nearly three decades of KSHV research the exact mechanism of KSHV transmission is
exceedingly unclear [29]. Modes of transmission differ depending on the background prevalence in
the population [30]. Transmission may occur during childhood and/or adulthood and is spread via
nonsexual and sexual routes [31]. KSHV was initially considered to only be transmitted via sexual
routes during the AIDS pandemic [16]. Now, sexual routes are known to occur in non-endemic
areas such as the United States and Western Europe where KSHV transmission is prevalent among
men who have sex with men [25]. Studies have shown that men who have sex with men have
roughly 40% higher rate of infectivity from that compared to heterosexual encounters [25].
Nonsexual routes of KSHV transmission occur in endemic areas such as Sub Saharan Africa where
much of the transmission is thought to occur during childhood [32]. Researchers have hypothesized
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that KSHV may be transmitted in the early stages of childhood via mother to child transmission
[33]. There are a variety of different instances where mother to child transmission has been shown
to occur. Mother to child transmission may occur during gestation where the child attains the
KSHV virus prior to being born. This transmission tends to occur when the mother contains KSHV
viral load in the female gential tract [31]. In other instances, the mother may transmit the virus
to the child via breastfeeding [34]. Studies have revealed that breast milk can contain KSHV
DNA[34]. One last and major instance of mother to child transmission is via salivary transmission.
Studies have identified instances where the mother premasticates the food of the infant to feed it
and the child later displays KSHV infection [35, 36].
Overall, KSHV can be detected in peripheral blood mononuclear cells, saliva, semen, breast milk
and prostate glands, but salivary shedding has been deemed the major reservoir of infectious
KSHV transmission[37, 38] . KSHV viral DNA is more frequently present and at higher levels
in saliva than any other fluid from KSHV patients undergoing treatment.[39]. Studies have also
demonstrated that the oral cavity plays a significant role in KSHV infections [40]. The oral cavity
contains cells such as: epithelial cells, B lymphocytes, lymphatic endothelial cells and fibroblasts
that KSHV is able to infect [41]. With that in mind, numerous labs, as well as our group, have
implemented the use of tonsils as a primary model to study the early stages of KSHV infections
[29, 53].
1.4 Kaposi Sarcoma Herpesvirus Life Cycle
KSHV has two life cycles following infection of host cells; latent and lytic replication. Both of
these phases are characterized by distinctive patterns of gene expression and both are essential for
the development of KSHV associated diseases [42]. KSHV is known to be predominantly in the
latent state with only 1-3% of cells associated with lytic replication at a time [43] . Establishment
of latent infection occurs initially during acute infection in immunosuppressed individuals [40].
In latent infection, the KSHV DNA genome persists as a circular episome in the nucleus where it
is in a quiescent state involving no production of virions. The purpose of latency is to allow the
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virus to establish a persistent infection, and, in some cases, latency can be maintained via immunemediated inhibition of lytic replication[44, 45]. There are a few latent associated genes expressed
in this phase including LANA (latency-associated nuclear antigen, vCyclin (viral cyclin), v-FLIP
(viral Fas like inhibitory protein), and various viral microRNAs [22].
LANA, a nuclear antigen that is 230 kDa and roughly 1162 amino acids long , is thought to
be a highly versatile protein during latency [44]. LANA is essential for maintaining, replicating
and segregating the viral genome throughout each generation of the host cell. LANA has the
capability of binding and interacting with various proteins, such as p53, to suppress transcriptional
activity and achieve inhibition of apoptosis and cell proliferation. These interactions allow LANA
to mediate viral persistence for KSHV [22]. v-Cyclin’s main duty is to function as a modulator
during latency to sustain cell proliferation and the cell cycle. v-Cyclin modulates phosphorylation
and inhibition of: CDK inhibitors, H1, histones, pRb protein, and p27 to form v-Cyclin-CDk6
complex. v-Cyclin-CDk6 mediates phosphorylation of nucleophosmin and facilitating interactions
between CDK6 , LANA, and nucleophosmin to promote KSHV latency [22, 46]. Homologous
to v-Cylin is another viral protein called v-FLIP. v-FLIP is an activator for both classical and
alternative NF-κB pathway which induce cell survival signals [47]. v-FLIP has the capability of
blocking apoptosis, viral reactivation and lytic replication in different cases [48]. For example,
blockage of apoptosis was performed by inhibiting procaspase 8 cleavage which blockage of viral
reactivation and lytic replication was performed by suppressing the AP-1 pathway [48].
During lytic infection, also referred to as the productive phase, KSHV replicates its genome and
produces infectious virions that are assembled and released from the cell via cellular lysis [40].
The majority of KSHV infected cells in humans are latently infected and contribute to persistent
infection [49]. But the presence of lytic genes is still critical for the pathogenesis of KSHVassociated diseases. The lytic replication genes that are present in infected cells are divided into
three classifications: immediate early, early, and late genes [44]. Lytic gene functions include, but
are not limited to, regulation of cell cycle, survival, and immune evasion [50]. After all lytic genes
are expressed, the commencement of virus assembly occurs in the nucleus which subsequently
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leads to the viral progeny to be released from the host cell [44]. It should be noted that latency
is reversible and has the potential of reactivating due to environmental conditions to enter lytic
replication [22]. There is a balance between these two life cycles to give KSHV the capability of
achieving persistent infection and achieving efficient spread of the virus to new hosts.
1.5 Kaposi Sarcoma Herpesvirus Cellular Tropism
KSHV exhibits an extensive cellular tropism as it infects a diversity of target cells in vitro and in
vivo.[52]. This broad cellular tropism is due to KSHV having distinct routes of entry depending
on the cell type [52]. In vivo, KSHV DNA has been detected in: human B-cells, peripheral blood
B-cells, epithelial cells, monocytes, fibroblast, keratinocytes, endothelial cells, and para endothelial
spindle cells [3], In vitro, KSHV infects endothelial cells, monocytes, fibroblasts, B-cells, and
epithelial cells lines of nonhuman and human origin [53].
We can also obtain clues as to the in vivo tropism of KSHV by observing the cell types in which it
causes disease. For example, KSHV DNA has been detected in lymphoproliferative diseases such
as MCD and PEL [54]. The immunological features of these diseases have led many to speculate
that MCD arises in naïve B-cells while PEL arises in post germinal center memory subsets [55,
56]. However, this may not always be the case, studies have revealed that KSHV infection can
cause MCD and PEL via defects in germinal center reactions and or reduction of memory cells [56,
57]. Overall, the initial cell types to be infected in both diseases is still unknown. In individuals
with KS, KSHV DNA has been found in a B-cell fraction of peripheral blood and endothelial cells
in malignant tumors [58, 59].
Altogether, KSHV has high susceptibility towards B lymphocytes in vivo, since it provides KSHV
with an environment where it is capable of establishing latency and persisting during the whole
life of their host [60]. Unfortunately, B lymphocytes have been notoriously difficult to infect with
KSHV in vitro, due to lack of appropriate receptor expression among other factors [61]. Our lab,
along with several other groups, have successfully performed in vitro infections on tonsil derived
B lymphocytes [62].
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1.6 Kaposi Sarcoma Herpesvirus Molecular Machinery
The structure of KSHV includes an electron-dense nucleocapsid with a tightly packaged double
stranded DNA virus (genome of 165kb and 90 open reading fragments) [63]. The capsid is
surrounded by a layer of tegument that contains several capsid associated proteins such as Open
Reading Fragments (ORFs): 45, 52, 11, 21, 33, 63, 64, and 75, several loosely associated proteins
and microRNAs. [2]. The last layer that surrounds the whole particle is the viral envelope which
consists of a lipid bilayer containing various viral glycoproteins. These viral envelope glycoproteins
are: gB (ORF8), gH (ORF22) ,gL (ORF47), gM (ORF39) , gN (ORF53),ORF4, and gpK8.1. The
conserved glycoproteins that are found in all herpesviruses are gB, gH,gL. gM, and gN [63]. The
conserved glycoproteins are thought to play an important role for virus entry and KSHV infection
since they mediate initial virus and host cell interactions (Figure 2) [2].
1.6.1 Kaposi Sarcoma Herpesvirus Viral Envelope Glycoproteins
As mentioned above, the glycoproteins that surround the viral envelope of KSHV are: gB
(ORF8), gH (ORF22) ,gL (ORF47), gM (ORF39) , gN (ORF53),ORF4, and gpK8.1. The KSHV
glycoprotein B is a 110 kDa protein that is thought to be a key player in the initial interaction for
KSHV entry into the cell and is thought to be the perpetrator of membrane fusion [2]. Glycoprotein
B (gB) undergoes cleavage and yields two linked polypeptides at 75kDa and 54kDA with complex
sugars and high mannose [64]. These conformational changes cause a shift in the target cells and
brings them to close proximity making fusion more likely to occur [64]. KSHV glycoprotein H
(gH) and glycoprotein gL (gL) form a non-covalent linked hetero-dimer complex where gH is 120
kDa and gL is 42 kDa. This hetero-dimer complex is found to be a vital epitope for KSHV specific
neutralizing antibodies in KS patients [65]. Previous studies have shown that gH reaches the cell
surface independently from gL [66]. The role of gH and its presence being essential in KSHV
entry remains poorly understood. KSHV glycoprotein M (gM) and glycoprotein N (gN) form a
heterodimer [67]. gN is utilized for the processing of gM. Both, gN and gM are overall known to
be involved in virus penetration [2]. Glycoprotein K8.1 (gpK8.1A) gives rise to two open reading
frames: gpK 8.1A and gp K8.1B. gp K8.1A consists of 228 amino acid protein while gp K8.1B
8

Figure 2. Visual representation of a Kaposi Sarcoma Herpesvirus. For the structure of KSHV there is a double
stranded DNA genome(165kb) contained within a capsid, a layer of tegument proteins between the capsid and the
lipid envelope, and viral glycoproteins embedded or associated with the lipid envelope. Adapted from: [2]

encodes a 167 AA glycoprotein sequence [68].There are a variety of glycoproteins that are either
still unknown or poorly understood in the KSHV infection process.
1.7 Kaposi Sarcoma Herpesvirus Viral Entry and Infection
Understanding how KSHV enters cells is of critical importance for the pathogenesis in the host and
for treatment strategies[2]. The current entry process of KSHV is poorly understood due to the fact
that KSHV possesses diverse modes of entry depending on the cell type. What is currently known
in the field is that KSHV has the capability of infecting cells by binding and entering the host
target cells through a sequential, multistep process that includes interactions among various host
cell receptors and various viral envelope glycoproteins. The interactions between glycoproteins
and host cell receptors facilitate attachment, fusion, entry, replication and assembly.[53]. The
mechanism of KSHV viral entry can be divided into a variety of different steps (Figure 3). The
initial step in the KSHV viral entry process consists of the binding of host cell receptors to the
KSHV viral glycoproteins [3]. Interactions of host cell receptors and KSHV viral glycoproteins
ultimately triggers signal transduction via various pathways that assist with viral entry and
trafficking[52]. This process may involve activation of tyrosine kinases that lead to recruitment of
signaling complexes that induce internalization [52]. For example, binding of KSHV to integrins
leads to phosphorylation of focal adhesion kinase (FAK), which leads to the activation of cell
processes such as adhesion, proliferation, endocytosis and cell death [3]. Induction of FAK is
9

also known to activate other kinases such as the family of Src kinases, PI3-K, Rho GTPases, and
Diaphanous 2 to regulate cell trafficking [3].
Following signal induction is viral entry into the target cells [3]. It should be noted that KSHV
employs different routes of entry depending on the cell type. For example, in fibroblasts, endothelial
cells, epithelial cells and monocytes, KSHV is shown to enter via endocytosis [3] . Endocytosis
within itself comprises different sub-routes of entry such as clathrin-mediated endocytosis,
phagocytosis, caveolae mediated endocytosis, and macropinocytosis [52]. In endothelial cells, the
route of endocytosis KSHV partakes in is macropinocytosis while in fibroblasts KSHV enters via
clathrin mediated endocytosis [69].
Once the virus is fully internalized into the endosomes, the KSHV viral envelope fuses with
endosomal membranes allowing release of the capsid into the cytoplasm [3]. The capsid is then
transported within the cytoplasm via dynein motors and microtubules to ultimately reach the
nucleus [70]. The virus moves to the nucleus where the viral capsid is released and delivers the
viral DNA [3]. This then leads to viral gene expression and host cell gene reprogramming. [3].
1.8 Kaposi Sarcoma Herpesvirus Host Cell Surface Receptors
As mentioned above, the initial step in the KSHV viral entry process consists of the binding of
KSHV viral glycoproteins to KSHV host cell receptors. It should be noted that KSHV host cell
receptors fall into two main categories: Cellular Binding Receptors and Cellular Entry Receptors
[71]. Cellular Binding Receptors are used to promote binding and concentration of the virus onto
the target cell. A known binding receptor for KSHV is Heparan Sulfate (HS) [72] . Heparan Sulfate
is a sulfated polysaccharide of the sulfate proteoglycan family that serves as an attachment factor
for a variety of viruses such as: KSHV [73], HIV [74], Hepatitis E [75], Dengue [76], and RSV
[77].
HS is present on various cell types: fibroblasts, endothelial cells, epithelial cells and monocytes
[2]. Within these cell types, the binding of HS with glycoproteins gB, gHgL, and K8.1 have been
shown to occur during the KSHV entry process [78]. To identify if HS was essential for KSHV

10

Figure 3.Visual representation of KSHV entry process. Adapted from:[3]

entry, individual studies pre-treated the target cells with soluble HS (a neutralizing agent against
HS) [2, 60, 64, 78, 79]. Results displayed that HS was dispensable for viral entry but that in the
presence of HS, interactions were enhanced for entry into cells [2].
Other studies have also demonstrated that heparan sulfates are dispensable in tonsillar derived B
lymphocytes [62]. This particular study removed HS via a heparinase treatment from the tonsillar
derived B lymphocytes and overall displayed that KSHV still had the capability of infecting these
cells. The combination of all these studies overall reveal that HS can be utilized as an attachment
factor to enhance entry but it is not essential for entry in all cell types [2].
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The second type of host cellular receptor are known as cellular entry receptors [71]. There are
various cellular entry receptors that KSHV is known to engage with depending on cell type.
The cellular entry receptors for KSHV include, but are not limited to, Ephrin receptors (Eph),
integrin receptors, cystine/glutamate antiporter (xCT), and Dendritic Cell-specific Intercellular
adhesion molecule-3-grabbing non-integrins (DC-SIGN) [52]. Ephrin receptors (Eph) are
type-I transmembrane proteins that are part of the receptor tyrosine kinase family [71]. The Eph
receptors consist of various forms and are vital for signaling pathways in cancer proliferation and
differentiation[80] . Eph receptors can be found on endothelial cells, epithelial cells, fibroblasts
cells, and B-cells [71]. One form of Eph receptor known as EphA2 can be used in the KSHV entry
process. Studies have shown that EphA2 is essential for entry in endothelial cells by knocking
down Eph2A and displaying no presence of infection after [81]. Studies have also indicated that
gHgL can bind to the EphA2 receptor and induce EphA2 phosphorylation, which ultimately leads
to internalization [82].
Integrins are cell surface receptors responsible for interactions between cells and the extracellular
matrix [71]. Studies have indicated that alpha and beta dimers of integrins serve as receptors for
KSHV infection in fibroblasts, monocytes, epithelial cells and endothelial cells [71]. Studies have
shown that KSHV gB interacts with different types of integrins such as: α3β1, αVβ3, and αVβ5 for
entry into these cells [2, 68, 72, 83]. gB possesses a binding motif (Arginine-Glycine-Aspartate,
also referenced to as: RGD) that is the potential binding site for these intergin host cell receptors
[78]. The interaction of gB with these integrins activates a cascade of signaling pathways that, in
turn, result in internalization of the virus. Besides the gB glycoprotein interaction, studies suggest
that integrins alone are indispensable in KSHV infection while others studies state otherwise. One
study suggests that integrins are critical for mediating entry, signal transduction, and viral-gene
expression for KSHV in endothelial cells, and fibroblasts[78]. But other studies reveal data that
KSHV utilizes heparan sulfates and Ephrin receptor routes, independent of integrins, to infect
endothelial cell lines[84]. Thus, the importance of integrins for KSHV entry in these specific cell
types remains largely unknown.
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Cystine/glutamate antiporter (xCT), is a 12-transmembrane, 501 amino acid glutamate/cysteine
exchange transporter protein that is 125kDa [85]. The primary function of xCT is cystine uptake
for intracellular glutathione synthesis to maintain intracellular redox balances during oxidative
stress[86]. xCT is highly expressed on malignant tumors including lymphomas, breast carcinoma,
glioma and prostate cancer [87]. Reports have shown that xCT is an integral component of a
complex that mediates cellular entry and fusion of KSHV [86]. xCT forms a complex with CD98,
integrins and other signaling molecules to promote KSHV entry and fusion in various cell types
such as: endothelial cells, fibroblasts and B-cells[87]. Studies have also shown that xCT has a
multi-functional role in KSHV infection to ultimately promote cell survival and tumorigenesis[87].
DC-SIGN also known as, Dendritic Cell-Specific ICAM-3-Grabbing Non-integrin, CD209, is a
type II C-type (calcium-dependent) lectin receptor [71]. DC-SIGN is highly expressed in cells
of the immune system such as dendritic cells (DCs), in dermal and mucosal tissues, monocytes,
macrophages, B lymphocytes from peripheral blood, and tonsillar B lymphocytes [88, 89]. In
monocytes, macrophages, dendritic cells, and B lymphocytes, glycoprotein gB has the ability to
bind to host cell receptor DC-SIGN [2, 88]. Studies have shown that gB binds to DC-SIGN in a
dose dependent manner, but this interaction has yet to be deemed essential for KSHV entry in any
cell type [90]. DC-SIGN is utilized as an entry receptor by many viruses such as Ebola virus ,
HIV-1, Hepatitis C, Ebola Virus, KSHV, SARS coronavirus, and Dengue virus [91]. Overall, DCSIGN is deemed important as it plays a critical role in the innate and adaptive immune response by
facilitating dendritic cell signaling, adhesion and migration [92].
1.9 B-cell Immunology
B-cells, also known as B-lymphocytes, are a class of white blood cells that are an essential
component in adaptive immune system [93]. B-cell development commences in the bone marrow
where B-cells acquire their antigen specific receptor and are released into the peripheral lymphoid
tissues for final maturation (Figure 4) [94]. In the peripheral lymphoid tissues, B-cell differentiation
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is subdivided into two distinctive pathways: T-cell dependent pathway or T-cell independent
pathway [95].
T-cell dependent pathways require the interaction between B-cells and T-cells for B-cell
differentiation [96]. T-cell dependent pathways occur in specialized micro-environments within
lymphoid tissues called germinal centers. The germinal center environment is subdivided into
two major compartments: Dark zone compartment and the light zone compartment. Within the
dark zone compartment, B-cells undergo proliferation, class-switch recombination and somatic
hypermutation; a process in which the function and affinity of their antigen receptors is refined via
recombination, random mutation, and selection. B-cells proliferate into centroblasts and centrocytes
but ultimately leave the dark zone as centrocytes [96]. In the light zone, the transformed centrocyte
acquires an antigen on their B-cell receptor (BCR), which they internalize, process and present to
helper T -cells via a Major Histocompatibility Complex Class II molecule (MHC II). Helper T-cells
recognize and interact with the MHC II molecule via their T-cell receptor and CD4+ molecule
[97]. Subsequently, T-cells up-regulate CD40L surface proteins and bind to the CD40 protein on
the centrocytes leading to the secretion of cytokines. Secretion of cytokines promote centrocytes
to undergo further rounds of proliferation, somatic hypermutation and exit the germinal center
reactions as plasmablast, memory cells, or plasma cells [97].
In T-cell-independent pathways, B-cells do not interact with T-cells nor undergo germinal center
reactions for B-cell differentiation [98]. T-cell independent pathways occur in the marginal zone
of the spleen which is located at the border of the red and white pulp adjacent to the marginal
sinus [99]. In this particular pathway, naive B-cells bind to T-cell independent antigens via their
BCR. T-cell independent antigens such as lipopolysaccharides (LPS) and polysaccharides (PS),
also referred to as Pathogen Associated Molecular Patterns (PAMPs), elicit repetitive epitope units
within their structure that ultimately provide the first signal of activation [100]. Pattern recognition
receptors known as Toll-like receptors (TLR), recognize this initial signal and interact with PAMPs
to elicit B cell proliferation and differentiation into plasmablast and plasma cells. In the T-cell
independent pathway, memory cells can not be induced due to the absence of T cell help [100].
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Overall, the goal of each pathway is to elicit antigen-induced activation in B-cells during their
process of development for them to produce plasmablast, memory (T-cell dependent pathway)
and plasma cells [100]. It should be noted that memory cells are critical cell types for the humoral
immune response as their duty is to recognize foreign antigens that have previously entered the
cell and elicit rapid immune responses [101]. While plasmablasts are a transient population of cells
that are in the process of maturating into plasma cells. Lastly, plasma cells are long lived cells that
primarily reside in the bone marrow and secrete high-affinity antibodies [102].
As a lymphotropic herpes virus, KSHV has affinity for B lymphocytes leading to development
of PEL and MCD [54]. So far, there have been a few in vitro KSHV infection models of B
lymphocytes focusing on the CD19+ population of B-cells [54, 103, 104].Within these studies,
data has suggested that KSHV infection may be driving B-cell differentiation in infected samples,
i.e. KSHV infected B-cells lead to plasmablast differentiation [103]. Our lab has pioneered the
detailed examination of B lymphocyte lineages in KSHV infection, and has characterized B
lymphocyte tropism of KSHV in human tonsil lymphocytes [62]. We demonstrated that a wide
variety of B-cell lineages are targeted by KSHV infection, and that CD138+ plasma cells (both the
CD20+ and CD20-) are highly targeted populations by KSHV. This susceptibility of plasma cells
is not due to CD138 (heparan sulfate) and overall B-cell infection is independent of HSPS. How
diverse populations of the B-cells are targeted by KSHV, and what means of cellular entry is used
by KSHV remains to be answered.
1.10 Justification for and Significance of the Study
Despite extensive KSHV research, there is still no effective treatment to fully eradicate KSHV
[105]. Additionally there is no standard guideline to manage the current KSHV associated
diseases [105]. KSHV treatments are dependent on the type of KSHV associated disease, the
tumor location ,the tumor progression, severity of the symptoms and immune system tolerance
[105]. KSHV treatments that are in use to combat this virus are highly variable depending on the
geographic location [105]. U.S treatment strategies include but are not limited to antiviral therapy,
antiretroviral therapy, excisional biopsy, radiation therapy, chemotherapy, immunotherapy, and
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protease inhibitors [105]. While other countries such as Sub Saharan Africa, where KS is the
predominant cancer in those living with HIV/AIDS ,do not have U.S treatments readily accessible
[106, 107].
The most common treatment for prevention of KSHV associated diseases in the U.S is antiviral
therapy [105]. In KSHV diseases associated with PEL and MCD, antiviral drugs have been shown
to reduce KSHV viral load. This outcome is due to these diseases expressing highly lytic phase
genes [108]. In KSHV-MCD several toxic chemotherapy treatments have also been utilized to
combat this disease [108]. Studies have overall shown that KSHV-KS does not respond well to
antiviral treatments due to the small quantity of lytic KSHV genes in the infected cells [105].

Figure 4. Scheme of the stages of B cell differentiation in human tonsil.

Highly active antiretroviral therapy (HAART) or HAART in combination with chemotherapy
have been implemented as treatment for people with KS and HIV/AIDS [109] .Whereas, the
incidence of KSHV has not declined in these individuals. Studies have demonstrated that some
individuals fully recover with these treatments while others display resistance to the medication
[110].This resistance is indicative that people living with KS and HIV/AIDS need more than
immune reconstitution to prevent the disease [62].
KSHV associated diseases consist of many challenges for treatment strategies due to its persistent
lifelong latent infection with recurring activation for active replication [49]. Exploring new
insights in the early stages of KSHV transmission is needed to offer new effective and less toxic
therapeutics for KSHV associated diseases [105]. Although KSHV glycoprotein and host cell
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receptor interactions have been well established on numerous cell types as described in the KSHV
host cell receptor section of this thesis, there is limited data available characterizing how KSHV
enters primary B lymphocytes.
Studies have shown that DC-SIGN, can be utilized as an entry receptor for KSHV infection in human
myeloid dendritic cells, macrophages, and activated peripheral blood B-cells [88].To evaluate if
DC-SIGN is required for KSHV infection in human activated peripheral blood B-cells, a previous
study blocked DC-SIGN expression on target cells with a DC-SIGN neutralizing antibody [antiDC-SIGN MAb] prior to infection. 24 hours post infection, the distribution of KSHV infection was
assessed. Results displayed that pretreatment of target cells with anti-DC-SIGN blocked ~90% of
KSHV infection. Study concluded that expression of DC-SIGN is essential for KSHV infection in
B-cells [89]. However, this conclusion is not valid for tonsil-derived B-cells, or any other B-cell
due to the fact that this study was strictly performed on peripheral blood B-cells and additionally
analysis of specific B-cell subsets in the blood was not performed. Thus, the role of DC-SIGN in
tonsil-derived B-cells for KSHV entry and in specific B-cell lineages remains unknown.
A previous study from our lab and our collaborators at the City of Hope, generated a mutant
KSHV virus lacking gH, but retaining all of the other KSHV viral envelope glycoproteins (KSHV∆gH) in order to characterize the requirement of glycoprotein H in KSHV biology [111] . This
study assessed the infectivity of KSHV-∆gH in numerous cell types in vitro such as epithelial
cells, endothelial cells, a B-cell line (MC116) and fibroblasts. Results revealed that glycoprotein
H is required for infection in epithelial cells, endothelial cells, and fibroblast, but not required in
MC116 B-cell lymphoma cells.
These previous studies have led us to take several approaches to elucidate the essential glycoproteins
and host cells receptors in KSHV entry and infection of tonsil-derived B lymphocytes. We will
test whether the cell surface receptor, DC-SIGN, is required for viral entry and infection in tonsil
derived B-cell lineages and whether the glycoprotein H is required for entry on tonsil derived
B-cell lineages.We will also combine these approaches with the KSHV-∆gH mutant virus in order
to determine whether manipulation of DC-SIGN affects entry of this mutant into B lymphocytes.
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Determining these roles will help provide novel targets for therapeutic intervention in KSHV
diseases and the prevention of KSHV transmission.

CHAPTER II-METHODOLOGY

2.1 Materials
Dulbecco’s Modified Eagle Medium (DMEM) with high-glucose and L-glutamine and no
sodium pyruvate was purchased from Caisson Labs (Smithfield, UT, US). Fetal Bovine Serum
was purchased from R&D Systems (Centennial,CO) .Trypsin-EDTA ,0.25%, sterile-filtered,
BioReagent, suitable for cell culture, 2.5 g porcine trypsin and 0.2 g EDTA . 4Na per liter of
Hanks’ Balanced Salt Solution with phenol red were obtained from Sigma Aldrich (St.Louis, MO).
Penicililin Streptomycin L-glutamine (PSG) was purchased from Corning (Corning, NY). RBC
lysing solution was created in house with 0.15M ammonium Chloride (Sigma Aldrich), 10mM
potassium bicarbonate (Bio Basic), 0.1 EDTA (Sigma Aldrich). Dimethyl Sulfoxide (DMSO) was
purchased from Bio Basic (Ontario, Canada). Roswell Park Memorial Institute Medium (RPMI)
was purchased from Cytiva (Marlborough, MA). DNase I (deoxyribonuclease I),Grade II, from
bovine pancreas, 100 mg was purchased from Sigma-Aldrich (St.Louis, MO). Primocin 500 mg
was obtained from Invivogen ( San Diego,CA) , Bovine Serum Albumin (BSA) was purchased
from Cytiva (Marlborough, MA), Sodium Azide was purchased from Sigma-Aldrich (St.Louis,
MO). Antibodies for flow cytometry were acquired from BD Biosciences (San Diego, CA) and
Biolegend (San Diego,CA): anti-human IgD-BUV395 ( BD 563823), anti-mouse CD77-BV510
(BD563630 ), anti-mouse CD138-BV650 ( BD 555462),anti mouse CD27-BV750 (BD 563328),
anti-mouse CD19-PerCPCy5.5 ( BD 561295), anti-human CD38-APC (BD 560158), anti-mouse
CD20-APCH7 (BL 302313), and anti-mouse DC-SIGN- PE-Cy7 (2µl/test BD 330114), Zombie
Violet™ Fixable Viability (BL 423113). Mojosort™ Human Pan B-cell isolation kit was purchased
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from Biolegend San Diego, CA(BL 480082) . Miltenyi CD209 (DC-SIGN) Microbeads Kit were
purchased from Miltenyi Biotec Inc Auburn,CA .(Miltenyi 130-092-868).
2.2 Cell lines
Cell free iSLK-derived BAC16-rKSHV-∆gH-eGFP was generated in the Ogembo laboratory at
City of Hope, Duarte, CA [111]. Cell free iSLK-derived BAC16-rKSHV-WT-eGFP were generated
as described in [112].CDw32 L cell lines were obtained from American Type Culture Collection
(ATCC), and underwent irradiation protocol as discussed in [29] De-identified human tonsil
specimens were obtained from the National Disease Research Interchange (NDRI) Note: The use
of deidentified tonsil specimens was not subject to IRB review as human subjects research.
2.3 Laboratory Equipment
Miltenyi Biotec QuadroMACs Magnetic Cell separator and MojoSort™ Magnet were utilized
to perform cell separation. Flow cytometry reading on all experiments was performed using BD
LSRFortessa Flow Cytometer. FlowJo Software & RStudio was utilized to analyze data and
perform statistical analysis.
2.4 Methods
2.4.1 Preparation of cell-free recombinant KSHV virions
iSLK cell lines harboring BAC16-KSHV-WT-eGFP [112] and BAC16-KSHV-∆gH-eGFP [111]
were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% Cosmic
Calf Serum (CCS), PSG, puromycin (1uL/mL), G418 (1uL/mL) , and hygromycin (8uL/mL) at
37°C in 5% CO2. For virus preparations, 12x T185 flasks at 80-90% confluence were stimulated
for 72 hours with 3mM sodium Butyrate and 2uM Doxycycline hyclate. At 3 days post induction,
supernatants were clarified by centrifugation at 1700rpm at 12min 4°C and filtered with a 0.45um
vacuum filter. Virions were pelleted out of clarified supernatant over 25% sucrose in TNE (50mM
Tris[pH7.4], 100mM NaCl, 0.1mM EDTA,pH7.4) by centrifugation at 22,000 rpm for 2 hours.
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Virus pellets were resuspended in 2ml TNE and stored at -80 °C. Infectious titer doses were
determined for
iSLK-BAC16-KSHV-WT-eGFP by serial dilution infection on human fibroblasts and quantified at
3 days post infection via flow cytometry, Infectious titer doses were determined for iSLK-BAC16KSHV-∆gH-eGFP by calculating equal genome copy number to that of iSLK-BAC16-KSHVWT-eGFP via quantitative PCR (qPCR).
2.4.2 Isolation of primary lymphocytes from Human Tonsil
De-identified human tonsil specimens were obtained from

the National Disease Research

Interchange (NDRI) following routine tonsillectomies. Less than 24 hours post-surgery, tonsil
specimens were shipped and delivered in DMEM+PSG to the laboratory. Primary lymphocytes
were extracted via dissection and maceration of tonsil tissues in RPMI media. Lymphocytecontaining media were passed through a 40µm filter, and pelleted at 1500rpm for 5 minutes.
Red blood cell lysing solution (0.15M ammonium chloride, 10mM potassium bicarbonate, 0.1M
EDTA) was utilized to lyse red blood cells present in the lymphocyte preparation. Following 3
minutes of RBC lysis, lymphocytes were diluted in 50ml of PBS, manually counted and pelleted
at 1500rpm for 5 minutes. Aliquots of 1e8 cells were resuspended in 1ml of freezing media (90%
FBS, 10% DMSO) and cryopreserved.
2.4.3 Magnetic Cell Separation of Total B-Lymphocytes from Tonsillar Primary lymphocytes
Tonsil primary lymphocyte suspensions were thawed at 37°, slowly diluted to 5ml with RPMI.
and pelleted at 1500rpm for 5 minutes. Pellets were resuspended in 1ml RPMI with 20%FBS,and
100µg/ml DNase I, and 100µg/ml Primocin. Cells were maintained in a low-binding 24 well plate
at 37 °C and 5% CO2 incubator for two hours. After recovery, total lymphocytes were counted and
Total human B cells were isolated using Mojosort™ Human Pan B-cell isolation kit (Biolegend
480082) according to manufacturer’s instructions. Bound cells that were non B-cells were retained
and maintained in 1ml RPMI, 20% FBS and 100ug/ml at 37 °C and 5% CO2 incubator.
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2.4.4 Infection of Total B lymphocytes with KSHV
Recombinant KSHV virion preparations were used at the dose needed to infect 20% of human
fibroblast cultures at 3 days post-infection (ID20) and were diluted in serum free media RPMI in a
total of 400µl for each 1 million total B lymphocytes. For experiments including KSHV-∆gH, the
WT virus was used at ID20 doses and KSHV-∆gH was used at an equivalent genome dose. In all
experiments Mock-infected cultures were included as an internal reference for the GFP positive
signal and to allow analysis of culture-specific effects. Cells in infection media were spinoculated
at 1000rpm for 30 minutes at 4˚C in 12x75mm round bottom tubes. After spinoculation, tubes
were incubated at 37˚C for an additional 30 minutes. After incubation, infected cultures were
transferred to X-ray irradiated CDW32 L cells in a 48 well plate and reconstituted with 20% fetal
bovine serum, 100ug/ml of Primocin and 1 million cells from the bound fraction of the B cell
isolation. Reconstituted lymphocyte cultures were incubated at 37˚C, 5% CO2 for the duration of
the experiment. At 3 days post-infection, cells were harvested for analysis by flow cytometry for
B-cells lineages and KSHV infection (See section 2.4.7).
2.4.5 DC-SIGN Neutralization
Total B lymphocytes were isolated as in 2.4.3 and were incubated with Human DC-SIGN/CD209
Antibody [anti-DC-SIGN mAb] (R&D system MAB161-100) at varying concentrations (0ug/ml,
2.5ug/ml, 5ug/ml) for 30 minutes on ice prior to infection, culture and analysis as described in
2.4.4.
2.4.6 DC-SIGN Depletion
Total B lymphocytes were isolated as described in 2.4.3 and were further separated into DC-SIGN+
(bound) and DC-SIGN- (unbound) fractions using CD209 (DC-SIGN) MicroBeads (Miltenyi 130092-868) according to manufacturer’s instructions. Following separation, half of the DC-SIGNB cells were reconstituted with DC-SIGN+ B cell fraction and the remaining cultures remained
depleted. These depleted and reconstituted samples were Mock-infected or infected with KSHVWT and KSHV-∆gH, cultured and analyzed as described in 2.4.4.
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2.4.7 Flow cytometry
At day 0 (baseline) or at 3 days post-infection (3 dpi) , 5e5 lymphocytes were aliquoted into a 96well round bottom plate and pelleted at 1500 rpm for 5 minutes. Resuspension of the pellet was
performed with 100µl PBS containing zombie violet fixable viability stain (BL Cat# 423113) and
incubated on ice for 15 minutes. After incubation 100ul PBS , containing the following: 2% FBS
and 0.5% BSA (FACS Block) was added to the wells. Cells were pelleted at 1500rpm 5 minutes
and resuspended in 200ul FACS Block followed by a 10 minute incubation on ice. Cells were
pelleted at 1500rpm for 5 minutes and resuspended in 50µl of PBS containing the following 0.5%
BSA and 0.1% Sodium Azide (FACS Wash), 10µl BD Brilliant Stain Buffer Plus and antibodies as
follows: IgD-BUV395 (2.5µl/test BD 563823), CD77-BV510 (2.0 µl/ test BD 563630), CD138BV650 (2µl/test BD 555462), CD27-BV750 (2µ/test BD 563328), CD19-PerCPCy5.5 (2.0µl/test
BD 561295), CD38-APC (10µl/test BD 560158), CD20-APCH7 (2ul/test BL 302313), and DCSIGN- PE-Cy7 (2µl/test BD 330114) and incubated on ice for 15 minutes. After incubation, 150µl
FACS Wash was added. Cells were pelleted at 1500rpm for 5 minutes followed by two washes
with FACS Wash. Cells were collected in 200µl FACS Wash for flow cytometry analysis. Sample
data and appropriate compensation controls were acquired on a BD Fortessa X20 flow cytometer
and analyzed using FlowJo Software (Table 1, Supplemental Figure 1).
2.4.8 RT-PCR
At 3 days post infection, 2e6 lymphocytes were harvested into Trizol and an equal volume of
DNA/RNA shield (Zymo Research R110-250) was added. RNA extraction was performed using
Zymo Directzol Microprep (Zymo Research R2060) according to manufacturer instructions.
RNA was eluted in 10µl H2O containing 2U RNase inhibitors and a second DNase step was
performed for 30 minutes using the Turbo DNA-Free kit (Invitrogen AM1907M) according
to manufacturer instructions. One-step RT-PCR cDNA synthesis and preamplification
of GAPDH, LANA and K8.1 transcripts was performed on 15ng of total RNA using the
Superscript III One-step RT-PCR kit (ThermoFisher 12574026) and 2µM outer primers for
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each target gene as follows: GAPDH outer forward (5’-TCGGAGTCAACGGATTTGGT-3’),
GAPDH

outer

reverse

outer

forward

reverse

(5’-

(5’-

(5’-

GGGTCTTACTCCTTGGAGGC-3’),

(5’-AATGGGAGCCACCGGTAAAG-3’),
CGCCCTTAACGAGAGGAAGT-3’),

ACCGTCGGTGTGTAGGGATA-3’),

K8.1

LANA

K8.1

outer

outer

reverse

LANA
outer
forward
(5’-

TCGTGGAACGCACAGGTAAA-3’). Duplicate no RT (NRT) control reactions were assembled
for each lineage/sample containing only Platinum Taq DNA polymerase (Thermofisher
15966005) instead of the Superscript III RT/Taq DNA polymerase mix. After cDNA synthesis
and 20 cycles of target pre-amplification, 2µl of pre-amplified cDNA or NRT control reaction was
used as template for multiplexed real-time PCR reactions using TaqProbe 5x qPCR MasterMix
-Multiplex (ABM MasterMix-5PM), 5% DMSO, primers at 900nM and probes at 250nM
against target genes as follows: GAPDH forward (5’-TCGGAGTCAACGGATTTGGT-3’),
GAPDH
probe
forward
(5’-

reverse

(5’-

GGGTCTTACTCCTTGGAGGC-3’),

(5’[HEX]-ACGCCACAGTTTCCCGGAGG-[BHQ1]3’)
(5’-AATGGGAGCCACCGGTAAAG-3’),
CGCCCTTAACGAGAGGAAGT-3’),

ACACAAATGCTGGCAGCCCG-[BHQ1]3’),

LANA
K8.1

LANA

LANA
probe

GAPDH

reverse
(5’

[6FAM]-

forward

(5’-

ACCGTCGGTGTGTAGGGATA-3’), K8.1 reverse (5’- TCGTGGAACGCACAGGTAAA-3’),
K8.1 probe (5’[FAM]-TGCGCGTCTCTTCCTCTAGTCGTTG-[TAMRA]3’) and analyzed using
a 40 cycle program on a Biorad real time thermocycler. Data is represented as quantitation cycle
(Cq) and assays in which there was no detectable Cq value were set numerically as Cq=41 for
analysis and data visualization.
2.4.9 Statistical Analysis
Data plots and statistical analysis were performed in Rstudio software (version 7.0 ) using ggplot ,
reshape, dplyr, and tidyverse packages. Statistical analysis was performed using R package: rstatix.
Specific statistical methods such as independent t-test and Pearson correlations were implemented.
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Specific statistical tests and the resulting values are described in detail in the corresponding figure
legends.
Table 1: Lineage definitions for lymphocyte subsets used in the study
B Lymphocytes
Subset

Molecular Markers

Plasma
Transitional

CD19 , CD20+/-, CD138+(Mid to High), CD38CD19+, CD138-, CD38Mid, IgD+ (Mid to High)

Plasmablast
Germinal Center
GC-Centrocytes

CD19+, CD138-, CD38High, IgD+ /- (mostly -)
CD19+, CD138-, CD38Mid, IgDCD19+, CD138-, CD38Mid, IgD-, CD77-

GC-Centroblasts

CD19+, CD138-, CD38Mid, IgD-, CD77+

Naïve
Marginal Zone Like
(MZ-Like)
Memory

CD19+, CD138-, CD38Low, CD27- , IgD+ (Mid to High)
CD19+, CD138-, CD38Low, CD27+ (Mid to High), IgD+ (Mid to High)

Double Negative

CD19+, CD138-, CD38Low, CD27-, IgD-

+

CD19+, CD138-, CD38Low, CD27+ (Mid to High), IgD-
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CHAPTER III-RESULTS

3.1 . Most DC-SIGN+ B-cells are Germinal Centers, Naives, and Transitional Lineages at
Baseline
We first wanted to establish the lineage-specific expression of DC-SIGN in tonsil-derived B-cells
prior to infection. This analysis allows us to determine if DC-SIGN expression correlates with
lineage-specific susceptibility to KSHV infection and also provides a baseline for comparison
of infected cultures to determine whether our lymphocyte culture system changes DC-SIGN
expression over time. These results reveal that for most tonsil lymphocyte preparations 10-15%
of tonsil-derived B-cells were positive for DC-SIGN (Figure 5A). When we performed lineage
analysis (Table 1, Supplemental Figure 1) on DC-SIGN positive B-cells, we determined that most
B-cell lineages, with the exception of MZ-like, were present within the DC-SIGN+ population and
germinal center, naive, and transitional lineages were highly represented (Figure 5B).
3.2 KSHV infection does not alter DC-SIGN expression on B-cells and expression of DCSIGN on KSHV-infected cells is highly variable.
To determine whether our culture system and/or KSHV infection alters the distribution of DCSIGN within B cell lineages, we performed KSHV infection and analysis at 3 dpi for 10 tonsil
lymphocyte preparations quantitating DC-SIGN+ B cells and the distribution of B cell lineages
within the DC-SIGN+ population for both Mock and KSHV-infected cultures. These results reveal
that there was no statistically significant change in overall DC-SIGN expression on B lymphocytes
in Mock vs. KSHV-infected cultures (Figure 5C, left panel). Moreover, we found that although
significant numbers of DC-SIGN+ B cells were present in KSHV-infected cultures, few of these
DC-SIGN+ cells were KSHV infected (as shown by the expression of the GFP reporter that is
constitutively expressed from the recombinant KSHV genome), indicating that infection is not
particularly enriched in the DC-SIGN+ fraction (Figure 5C, right panel). However, since overall
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KSHV infection is low in these cultures (~1% of B-cells) we analyzed the data to examine the
frequency of DC-SIGN expression on KSHV-infected (GFP+) cells specifically (Figure 5D).
This data shows that the presence of DC-SIGN in KSHV-infected lymphocytes is highly variable.
Finally, we analyzed the B cell lineage distribution for DC-SIGN+ B cells in Mock and KSHVinfected conditions and found no significant influence of infection on DC-SIGN distribution
(Figure 5E). Taken together, these data show minimal impact of infection on DC-SIGN expression
and distribution indicate that expression of DC-SIGN within infected cells varies substantially
based on donor. Thus these results do not strongly support or refute the hypothesis that DC-SIGN
is used as an attachment receptor for KSHV infection in B lymphocytes.
3.3 Neutralization of DC-SIGN increases KSHV Infection of B lymphocytes
In order to more directly determine whether DC-SIGN is required for KSHV entry into B
lymphocytes, we performed experiments in which we blocked DC-SIGN using increasing
concentrations of a DC-SIGN neutralizing antibody prior to infection and assessed the magnitude
and distribution of KSHV infection at 3 dpi. Surprisingly, these results revealed increased KSHV
infection at 3 dpi in most samples (Figure 6A). In order to account for the variable susceptibility
of tonsil samples to KSHV infection in our model [62], we analyzed this data as a change in GFP
using controls with no antibody treatment as a normalization factor. In this analysis we can clearly
see that the majority of tonsils included in this analysis show increased infection in response to
DC-SIGN neutralization, and the difference was statistically significant (p=0.02) at the 5µg/ml
dose (Figure 6B).
Next, we wanted to determine whether neutralization of DC-SIGN influences the distribution of
KSHV infection within B-cell lineages. In these experiments, if a particular lineage shows decreased
targeting by KSHV in the presence of DC-SIGN neutralization, we can conclude that DC-SIGN is
important for viral entry in that cell type. Our results show no statistically significant increase or
decrease in KSHV infection of any specific B-cell lineage. However, infection of memory, MZ-
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Figure 5: DC-Sign expression in human tonsil with and without KSHV infection. (A) Flow cytometry
analysis of DC-SIGN expression on the surface of viable B cells in 11 unique tonsil lymphocyte specimens at
day 0 (baseline). (B) Analysis as in (A) showing the distribution of B cell subsets within DC-SIGN+ B cells.
Red diamonds indicate the mean of 11 tonsil samples. (C) DC-SIGN expression at 3 days post-infection (dpi) in
Mock-infected and KSHV-infected cultures (left panel, n.s.) or in KSHV-infected GFP+ B cells (right panel). (D)
Frequency of DC-SIGN expression on GFP+ B lymphocytes in KSHV-infected cultures at 3 dpi. (E) Distribution
of B cell lineages within DC-SIGN+ B-cells as in (B) for Mock and KSHV-infected cultures at 3 dpi (n.s.). Where
indicated, data point color scheme indicates unique tonsil specimens and can be compared between sub-panels
within each portion of the figure.
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like and naive B-cells was increased in most of the samples (Figure 6C). These results, therefore,
do not identify any B-cell subset in which DC-SIGN is critical for entry.
We next wanted to determine whether increased the overall infection we observed with DC-SIGN
neutralization (Figure 6B) was correlated with changes in infection of any B-cell subsets. In order
to examine this, we plotted the change in frequency of GFP within B cell subsets against overall
change in GFP frequency at the 5µg/ml neutralizing antibody dose and calculated correlation
coefficients via the Pearson method (Figure 6D). Although power analysis indicates that these
correlations are not strong enough to be statistically significant with this sample number, we
observe that samples with increased GFP also displayed increased proportions of infected plasma,
MZ-like and memory B-cell lineages. These observations indicate that these particular lineages do
not depend upon DC-SIGN for KSHV entry.
3.4 Neutralization of DC-SIGN increases Plasma Cell frequency in KSHV-infected cultures
In order to determine whether the increase in GFP+ B-cells with DC-SIGN neutralization was due
to increased frequency or targeting of a specific B-cell subtype, we performed lineage analysis on
these samples. Analysis of overall lineage frequencies (infected and uninfected) in these cultures at
3 dpi revealed that most lineages did not change with DC-SIGN neutralization in either the Mock
or KSHV-infected conditions (Figure 7A and Figure 7B). However, we did observe a statistically
significant increase in the plasma cell population at the 5µg/ml dose only in the KSHV-infected
conditions (Figure 7A). This observation is particularly interesting given our recent publication
showing that plasma cells are highly targeted by KSHV early in infection [62].We hypothesized
that DC-SIGN neutralization was increasing overall infection by increasing targeting of B-cell
lineages that undergo lytic replication, thereby acting as a point of expansion for the virus. To
test this hypothesis, we performed RT-PCR analysis for LANA (a latent gene) and K8.1 (a lytic
gene) on 8 unique tonsil specimens with and without DC-SIGN neutralization at 5µg/ml. These
results show that there is no difference in lytic gene expression between untreated cultures and
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Figure 6: Effect of DC-SIGN neutralization on KSHV infection in tonsil B lymphocytes. (A) Flow cytometry
analysis of KSHV infection of 10 unique tonsil specimens based on GFP+ B lymphocytes at 3 dpi with indicated
doses of DC-SIGN neutralizing antibody (n.s.) (B) analysis as in (A) normalized within samples to the 0µg/ml dose
in order to remove between-sample variability. p=0.02 comparing 0µg/ml to 5µg/ml using student’s T-test with
Holm correction for multiple comparisons). (C) Analysis of frequency of plasma cells within viable B cells in Mock
or KSHV-infected cultures at 3 dpi with indicated doses of DC-SIGN neutralizing antibody. p=0.05 comparing 0µg/
ml to 5µg/ml in KSHV-infected conditions using student’s T-test with Holm correction for multiple comparisons.
(D) Flow cytometry analysis based on the distribution of GFP+ B lymphocytes within each B-cell lineage at 3dpi
with indicated doses of DC-SIGN neutralizing antibody (n.s) (E) Normalized correlation analysis showing linear
relationships (Pearson’s correlation coefficient) comparing the change in frequency of GFP within B cell lineages
and the change in overall GFP frequency at 5µg/ml neutralizing antibody dose (F) Taqman RT-PCR analysis on 8
unique tonsil specimens with duplicate technical replicates for each reaction condition showing expression of LANA
(latent) and K8.1 (late lytic) genes normalized within-reaction to GAPDH housekeeping gene expression (n.s.).
Where indicated, data point color scheme indicates unique tonsil specimens and can be compared between subpanels within each portion of the figure.
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cultures treated with DC-SIGN neutralizing antibodies (Figure 7C). These results suggest that
the mechanism for increased infection with DC-SIGN neutralization is not increased viral spread
within the cultures.
3.5 KSHV gH is not required for KSHV infection of tonsil derived B lymphocytes
In a recent study from our laboratory and our collaborators at the City of Hope, a mutant KSHV
virus lacking gH, but retaining all of the other KSHV viral envelope glycoproteins (KSHV-∆gH)
was generated to characterize the requirement of gH in KSHV entry for adherent cells such as
epithelial cells, endothelial cells, a B-cell line (MC116) and fibroblasts. Results revealed that
gH is required for entry in the adherent cells, but was not required for entry into the MC116
lymphoma cell line[111] . These results suggest that gH may be dispensable for entry into B-cells.
In order to test this hypothesis in our primary tonsil lymphocyte system, we utilized the same
mutant virus that was constructed for this previous study, which lacks gH but retains all the other
KSHV glycoproteins (KSHV-∆gH). We performed infections with 7 unique tonsil lymphocyte
samples and performed infections with KSHV-WT, KSHV-∆gH and Mock infection as described
above, and assessed the distribution of KSHV infection at 3 dpi using flow cytometry. It should
be noted that because KSHV-∆gH cannot infect fibroblasts we cannot use our normal system
for functional titration of the virus stock to normalize infection. Thus, for these experiments
we performed titration of the KSHV-WT stock as usual on fibroblasts to determine the optimal
infectious dose, and then used genome quantitation of both KSHV-WT and KSHV-∆gH virus
stocks in order to calculate an equivalent genome dose for KSHV-∆gH. These results reveal that,
overall in the data set, KSHV-∆gH infects tonsil-derived B cells at levels comparable to those
seen with KSHV-WT. However, within tonsil samples, 4 of 7 samples showed higher levels of
GFP+ B lymphocytes in KSHV-∆gH compared to WT (Figure 8A). We wanted to determine
whether the difference in infection efficiency with KSHV-WT vs. KSHV-∆gH was related to the
levels of B-cell subsets in the tonsil samples at the time of infection. To do this analysis, we
calculated the difference between the percent of GFP+ B cells with each virus on a per-sample
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basis (GFP in KSHV-∆gH - GFP in KSHV-WT) and compared this value to the sample-specific
baseline frequency of each B-cell lineage. This data reveals that KSHV-∆gH infectivity is highly
correlated with baseline levels of double negative B cells (an atypical memory B cell subtype), but
that KSHV-∆gH had lower infectivity in samples with high levels of transitional B cells (Figure
8B). These results may suggest that KSHV infection of transitional B-cells relies more heavily
upon gH-dependent entry mechanisms compared to entry into double negative B-cells. When we
examined the distribution of GFP within B-cell lineages at 3 dpi for these experiments, we found
that there was no significant difference in B-cell targeting between KSHV-WT and KSHV-∆gH
(Figure 8C). Finally, we wanted to determine whether the distribution of B-cell lineages within
the infected (GFP+) fraction was different between KSHV-WT and KSHV-∆gH. This analysis
showed that there was also no significant difference between KSHV-WT and KSHV-∆gH infection
(Figure 8D). Thus, neither the amount of infection within any B-cell subset nor the proportion of
B-cell subsets within the infected fraction differed between KSHV-WT and KSHV-∆gH. Taken
together, these results indicate that KSHV-∆gH (a virus which is globally defective in non-B cell
types) can infect primary B cells, and displays similar infectivity and B cell lineage tropism when
compared to KSHV-WT. We would conclude from this data that overall susceptibility of individual
tonsil specimens to infection with KSHV-∆gH is dependent upon the B-cell composition of the
specimen, suggesting that gH does play a role in entry into B lymphocytes. However, gH is not
strictly required for KSHV entry into any B-cell lineage, suggesting that this glycoprotein does not
play a pivotal role in KSHV infection of B lymphocytes in human tonsil.
3.6 Depletion of DC-SIGN in KSHV-WT and KSHV-∆gH infections reveals multiple, entry
mechanisms for KSHV in tonsil B lymphocytes
In order to examine whether KSHV-∆gH uses DC-SIGN to enter into B lymphocytes and to
validate our earlier DC-SIGN neutralization data (Figure 6) via another method, we performed
experiments with 6 unique tonsil specimens where we isolated total B lymphocytes and performed
a second step where we separated DC-SIGN+ and DC-SIGN- B-cells. Because DC-SIGN+ cells
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Figure 8: KSHV-∆gH infection in tonsil B lymphocytes. (A) Flow cytometry analysis of 7 unique tonsil
specimens infected with KSHV-WT and KSHV-∆gH based on GFP+ B lymphocytes at 3 dpi (B) Correlation
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represent a minor population in tonsil B-cells (Figure 5A) we did not have sufficient cell numbers
to infect the populations separately. Therefore we adopted a strategy where we either infected
DC-SIGN-depleted populations or reconstituted the depleted population with DC-SIGN+ B cells
prior to infection. Analysis of KSHV infection in these cultures revealed that KSHV-WT infection
is uniformly higher in DC-SIGN reconstituted cultures compared to DC-SIGN depleted cultures.
This trend was similar in KSHV-∆gH infected cultures with the exception of one tonsil sample
in which infection was increased in reconstituted culture for KSHV-WT and decreased in the
same condition with KSHV-∆gH (Figure 9A). Next, we examined the distribution of GFP within
B-cell lineages for DC-SIGN depleted vs. reconstituted cultures in order to determine whether
DC-SIGN is required for entry into any particular B-cell subset. Consistent with our neutralization
data, depletion of DC-SIGN did not abolish infection of any B-cell lineages with KSHV-WT.
Consistent with our previous analysis (Figure 8) there was no statistically significant difference
in infection comparing WT to ∆gH for either depleted or reconstituted fractions. For KSHV-WT,
although infection of most lineages tended to be higher in the reconstituted fractions, there was
no significant difference between DC-SIGN depleted and reconstituted cultures for any lineage
with KSHV-WT. Results were similar for KSHV-∆gH with the exception of centrocytes (the
CD77 negative sub-population of germinal center B cells) where infection was absent in the DCSIGN depleted culture vs. the DC-SIGN reconstituted culture (p=0.03) (Figure 9B). These results
support our previous conclusions that DC-SIGN plays a minor role as a receptor for KSHV entry
into tonsil-derived B cells, and that the KSHV glycoprotein gH is not required for entry into any
B-cell lineages. However, our data reveals that in the absence of both the DC-SIGN receptor
and the gH glycoprotein, KSHV cannot infect centrocytes. This implies that KSHV has only two
entry mechanisms for centrocytes: (1) a gH-dependent mechanism that uses a receptor other than
DC-SIGN, and (2) a gH-independent mechanism that uses DC-SIGN as the receptor. In KSHVWT, both entry mechanisms are functional and no difference is seen when DC-SIGN is depleted
because the gH-dependent entry mechanism is intact. When gH is absent but DC-SIGN is present
(KSHV-∆gH reconstituted) entry into centrocytes is mediated by the interaction of another KSHV-
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Figure 9: Effect of DC-SIGN Depletion on KSHV-WT and KSHV-∆gH infection in tonsil B lymphocytes. (A)
Flow cytometry analysis of 6 unique tonsil specimens in which DC-SIGN+ cells were depleted or depleted fractions
were reconstituted with isolated DC-SIGN+ B cells prior to KSHV infection with KSHV-WT or KSHV-∆gH and
analyzed 3 days post infection (n.s.) (B) analysis as in (A) showing distribution of infected (GFP+) cells within
B-cell lineages. *p=0.03 for depleted vs. reconstituted within KSHV-∆gH infection of centrocytes (C) Model for
entry mechanisms in the presence and absence of DC-SIGN and/or ∆gH for centrocytes.

gp and DC-SIGN. When gH is absent and DC-SIGN is absent, KSHV has no entry mechanism for
centrocytes (Figure 9C).
Taken together, our examination of the roles of KSHV-gH and cellular DC-SIGN reveals that:
(1) KSHV-gH is not required for entry into tonsil-derived B lymphocytes.
(2) KSHV-gH can participate in KSHV entry into centrocytes via a DC-SIGN independent entry
mechanism.
(3) DC-SIGN is not necessary for KSHV entry into any B-cell lineage
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(4) DC-SIGN does play a role in KSHV entry into tonsil-derived B-cells, but in all B-cell subtypes
alternative entry mechanisms exist.
Our results presented in this study provide a first glimpse into the complexity of KSHV entry in
the lymphocyte compartment and highlight that multiple lineage-dependent entry mechanisms
are employed by KSHV which depend upon multiple cellular receptors and multiple KSHV
glycoproteins. Further studies are needed to establish the roles of additional receptor-gp interactions
in these important cell types in order to rationally design therapies and vaccine strategies that will
effectively limit KSHV entry into, and spread within, the human immune system.
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CHAPTER IV-DISCUSSION & FUTURE DIRECTIONS
DC-SIGN is deemed important for the body’s innate and adaptive immune system for many reasons.
DC-SIGN has the responsibility of recognizing and capturing pathogens, facilitating dendritic
cell signaling, adhesion and migration, and overall initiating T cell responses [92]. DC-SIGN is
highly expressed in cells such as dendritic cells (DCs), dermal and mucosal tissues, monocytes,
macrophages, B lymphocytes from peripheral blood, and tonsillar B lymphocytes [88, 89]. The
role of DC-SIGN as a receptor for various viruses such as HIV-1, HCV, Ebola virus, CMV, dengue
virus, and the SARS coronavirus has been well characterized. DC-SIGN is known to facilitate
viral entry for KSHV, in human myeloid dendritic cells, macrophages, and activated peripheral
blood B-cells.
However, the existing literature on how DC-SIGN facilitates KSHV entry in tonsil derived B
lymphocytes is highly unknown. The only known study to perform an in-depth analysis on the
role of DC-SIGN as an entry receptor for KSHV infection was performed by Rappocciolo et.
al. in 2008 [89]. This particular study utilized peripheral blood B-cells that were activated with
CD40 ligand (CD40L) and interleukin 4 (IL-4) prior to infection to manipulate the proliferation
of cells in vitro. Wild-type KSHV virons derived from BCBL-1 PEL cells were used to infect
activated peripheral blood B-cells, and RT PCR was utilized to quantitate the copies of KSHV
DNA present in the cells after KSHV infection. In contrast, our studies utilized iSLK derived
BAC16 recombinant KSHV virus and resting tonsil derived B lymphocytes with no additive
stimulant due to our recent publication[62] showing that tonsil derived B lymphocytes do not need
to be activated for infectivity within our culture model. Importantly, we utilized multi-color flow
cytometry for our analysis method which allows us to see KSHV infection using the constitutively-
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expressed GFP reporter present in the BAC16 genome alongside surface antigen markers for B cell
lineages, allowing us to examine not only the total amount of infection in all B-cell, as was done
in Rappocciolo et. al., but also infection of specific B-cell subtypes on a per-cell basis. Thus, our
studies, for the first time ever, provide an in-depth report into the role of DC-SIGN for KSHV entry
in tonsil derived B lymphocytes that provides insight into whether DC-SIGN influences the B-cell
lineage-specific tropism of KSHV. Moreover, although DC-SIGN is known to be expressed on B
cell in both peripheral blood and tonsil, this study establishes the B-cell lineage distribution of DCSIGN in tonsil for the first time and shows that DC-SIGN expression is variable based on donor,
and most DC-SIGN+ B-cells in tonsil are germinal center, naive, and transitional phenotypes.
When we employed a neutralizing antibody to disrupt any interaction between DC-SIGN and
KSHV glycoproteins, we observed significantly increased KSHV infection at the highest dose
(5µg/ml), which was also the optimal dose for inhibition of DC-SIGN - ICAM3 interaction during
characterization of the neutralizing antibody by the manufacturer. These results differ from those
reported in Rappocciolo et. al., where use of the same anti-DC-SIGN neutralizing antibody clone
but at much higher concentrations (20µg/ml) effectively blocked KSHV infection of activated
peripheral B-cells[89]. Our analysis of the distribution of KSHV infection within B-cell lineages
did not reveal any change in KSHV targeting of B-cells with DC-SIGN neutralization, and RTPCR results show no increase in lytic replication in culture where the neutralizing antibody was
used. Thus our data provides no evidence that the increase in overall infection with DC-SIGN
neutralization is a result of altered KSHV targeting or spread. We did observe an increase in total
plasma cell numbers in DC-SIGN neutralized, KSHV-infected lymphocyte cultures. Our previous
work has shown that our lymphocyte culture system does not favor the survival of plasma cells but
KSHV infection increases overall plasma cell numbers at 3 dpi. Recently, activation of DC-SIGN
signaling via antibody binding was shown to promote survival of B lymphoma cells [113]. Thus,
the combination of DC-SIGN neutralization and KSHV infection may synergistically promote
the survival of plasma cells in our culture system and we speculate that the presence of plasma
cells promotes KSHV infection via unknown mechanisms that are possibly related to the cytokine
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milieu. Overall our results collectively show that DC-SIGN is not required for KSHV entry into
any B-cell lineage.
The KSHV viral envelope is known to consist of conserved viral glycoproteins: gB, gH, K8.1
and gL found in all herpes viruses. These specific glycoproteins are thought to mediate KSHV
attachment, fusion and entry into host target cells. To date, it is unknown which viral glycoproteins
are essential for KSHV entry in tonsil derived B lymphocytes. We recently showed that gH is
essential for KSHV entry into epithelial cells, endothelial cells and fibroblasts but is not required
for entry into the MC116 B-cell lymphoma cell line. The current study extends these findings and
shows that gH is also not required for entry into primary tonsil lymphocytes. Interestingly, our
results revealed tonsil donor-specific differences in the infectivity of KSHV-∆gH compared to
KSHV-WT, and that these differences are correlated to the frequencies of transitional and double
negative B-cells in the original tonsil sample. Moreover, our experiments in which we employed
depletion of DC-SIGN+ B-cells show that there is a gH-dependent mechanism for KSHV entry
into centrocytes. These data collectively demonstrate that, although gH is not strictly required for
entry into any B-cell type, there are gH-dependent entry mechanisms in tonsil-derived B-cells.
Our work presented here highlights that gH and DC-SIGN are not critical for entry in tonsil derived
B cells, but both factors can play a role in KSHV entry of specific B-cell lineages. Our results
clearly indicate that KSHV has multiple diverse entry mechanisms in tonsil lymphocytes which
remain to be established.
Our study does have some limitations that require further research. In particular, for the neutralization
experiment we chose to utilize a neutralizing antibody that may not be optimal for the inhibition
of DC-SIGN and KSHV glycoprotein interactions. The anti-DC-SIGN antibody we utilized is
optimized to neutralize the interaction of DC-SIGN with ICAM-3/CD50. It should be noted that
the DC-SIGN receptor is a tetramer protein composed of four individual domains: the C-terminal
carbohydrate recognition domain (CRD), the neck-repeat region, the transmembrane domain, and
the N terminal cytoplasmic tail [114]. Due to DC-SIGN’s role in the process of viral infection
and its structural complexity, many groups believe that blocking the sugar binding site, I-CAM-3
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epitope in the carbohydrate recognition domain (CRD) will overall inhibit DC-SIGN and not allow
the virus to enter [114]. This assumption is believed to be true because the ICAM-3 epitope is
located in the center of the carbohydrate recognition domain where most molecular processes
are mediated in the DC-SIGN receptor [114]. Importantly, the biochemistry of any interactions
between DC-SIGN and KSHV glycoproteins has not been established. The fact that our results
show increased infection with DC-SIGN neutralization could imply that the neutralizing antibody
may be binding to a different epitope on DC-SIGN and that the antibody is not neutralizing the
actual interaction of the viral glycoproteins to DC-SIGN. More research is needed to decipher the
real interactions between DC-SIGN and KSHV glycoproteins to be able to fully neutralize those
specific interactions. It will be interesting in future studies to explore the actual interactions of the
virus with the host cell receptor by utilizing a Fluorescence Resonance Energy Transfer (FRET)
immunoassay to detect and track the specific interactions and subsequently develop accurate
neutralizing antibodies against the neutralizing epitopes on DC-SIGN. Moreover, our results with
DC-SIGN neutralization highlight the need to better establish the role of DC-SIGN signaling in
our tonsil lymphocyte cultures and its impact on KSHV infection.
Our study is also limited on the fact that only one conserved glycoprotein for KSHV was studied,
glycoprotein gH. Future studies are needed to determine if the other conserved glycoproteins: gB,
gM, gN, and gpK8.1 are essential for KSHV entry. In order to study this, mutant viruses for each
individual glycoprotein need to be produced. With the production of these mutant viruses we will
have the opportunity to unravel different entry mechanisms for KSHV in tonsil derived B-cells
and to determine what viral glycoproteins are essential for entry. Furthermore, studies are needed
to establish the roles of additional receptor-gp interactions in these important cell types in order to
rationally design therapies and vaccine strategies that will effectively limit KSHV entry into, and
spread within, the human immune system.
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APPENDIX

Supplemental Figure 1: Gating scheme for B cell lineages by flow cytometry
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